All data is delayed
See More

Aspen: Earning to between rise 18%-24%

Aug 30 2012 14:45
I-Net Bridge

Company Data


Last traded 289
Change 3
% Change 1
Cumulative volume 1816191
Market cap 0

Last Updated: 02-10-2015 at 05:00. Prices are delayed by 15 minutes. Source: McGregor BFA

Related Articles

Aspen buys GSK Aussie drugs for R2.2bn

Drug firms win R2.5bn tender

Aspen unit to buy drug portfolio from GSK

Aspen buys GSK brands

JSE higher, led by Aspen drug deal

Aspen prepared to help bridge ARV shortages

Johannesburg - Aspen Pharmacare Holdings [JSE:APN] said on Thursday that it expected its diluted normalised headline earnings per share from continuing operations to rise between 18% and 24% in the year ended June‚ from the previous comparable period.

Headline earnings per share are expected to climb between 21% and 27%‚ from the same period a year ago‚ while earnings per share are expected to between 4% and 10% higher.

The growth in earnings per share has been reduced as a result of capital profits on the disposal of discontinued businesses and products in the present year being lower than in the prior year‚ it said.

aspen pharmacare holdings  |  shares


Read Fin24’s Comments Policy publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Company Snapshot

We're talking about:


With infrastructure spending having been identified as one of the key focus areas of the National Development Plan, tradesmen will continue to play a critical role in growing the South African economy through their skills..

Money Clinic

Money Clinic
Do you have a question about your finances? We'll get an expert opinion.
Click here...

Voting Booth

A 30% a month return on investment is:

Previous results · Suggest a vote